HR-4348-119
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 463.
Sponsored by Christopher Smith (R-NJ)
What it does
This bill would reauthorize two federal public health programs through 2030 that were previously authorized through 2025: (1) the national strategy and regional centers of excellence for vector-borne diseases under the Public Health Service Act, and (2) enhanced support grants to state and local health departments for addressing vector-borne diseases. It would also make a minor technical update to the consultation process for the national strategy and add language emphasizing capacity-building for disease identification, reporting, prevention, and response.
Who benefits
People living in tick- and mosquito-heavy regions who are at risk for diseases such as Lyme disease, Rocky Mountain spotted fever, West Nile virus, and other vector-borne illnesses. State and local health departments that receive federal grants to build surveillance and response capacity. Researchers and staff at regional centers of excellence who would continue to receive federal funding. Rural and suburban communities where tick exposure is highest. Patients who may benefit from improved early detection and reporting infrastructure.
Who is hurt
Taxpayers who bear the cost of continued federal spending on these programs. Competing public health programs that may face indirect budget pressure if discretionary funding is constrained. The Tick-Borne Disease Working Group, which is removed from the formal consultation process for the national strategy — a minor reduction in that body's advisory role.
Supporters argue
Supporters argue that vector-borne diseases are a growing public health concern — CDC data show reported cases of tick-borne illnesses have more than doubled since 2004, with over 50,000 cases reported annually in recent years. They contend that the regional centers of excellence and health department grants have built measurable surveillance and response infrastructure that would lapse without reauthorization, leaving communities less prepared to detect and contain outbreaks.
Opponents argue
Opponents argue that reauthorizing these programs without a formal performance review or updated funding levels amounts to extending programs on autopilot, regardless of whether they have achieved their goals. They contend that removing the Tick-Borne Disease Working Group from the consultation process reduces expert oversight of the national strategy, and that Congress should conduct rigorous oversight of existing programs before extending them for another five-year cycle.
Constitutional context
Congress funds these programs under the Taxing and Spending Clause (Art. I, §8, cl. 1) and regulates public health infrastructure under the Commerce Clause (Art. I, §8, cl. 3). No significant constitutional issues are raised by this reauthorization of an existing program.
Checks and balances
Congress retains authority by setting the five-year authorization window; HHS and CDC implement the programs and are subject to annual appropriations oversight by Congress.
Historical precedent
The original Kay Hagan Tick Act was enacted in 2019 and first authorized these programs through 2025; this bill follows the same reauthorization structure as that prior legislation.